Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/7/2025

Doxepin Safety Profile in Elderly Female Patients with Insomnia

Common Side Effects at Low Doses (3-6 mg)

  • The American Academy of Sleep Medicine recommends low-dose doxepin (3-6 mg) for elderly female patients with insomnia, as it has a remarkably benign safety profile with adverse effects comparable to placebo, showing only a mild increase in somnolence at the 6 mg dose (risk difference +0.04) and no clinically significant next-day impairment, anticholinergic effects, or withdrawal symptoms 1, 2
  • Somnolence is a common side effect, with a mild increase observed primarily at 6 mg dose, with minimal impact at 3 mg 1, 3
  • Headache is a reported side effect at both 3 mg and 6 mg doses, though incidence is comparable to placebo 1
  • Diarrhea is noted at 3 mg dose in meta-analyses 1
  • Upper respiratory infection is observed at 3 mg dose 1
  • The American Academy of Sleep Medicine and VA/DoD guidelines recognize that adverse event rates may increase with longer treatment duration, emphasizing use at the lowest effective dose for the shortest duration 3

Clinical Pitfalls to Avoid

  • The American Academy of Sleep Medicine warns against confusing low-dose (3-6 mg) with antidepressant doses (25-300 mg), as the side effect profile is dramatically different 1

REFERENCES

1

clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an american academy of sleep medicine clinical practice guideline. [LINK]

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2017

2

Insomnia Treatment Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3

Effectiveness of Doxepin for Insomnia [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025